JP2016534057A - 放射線傷害を処置および予防する方法 - Google Patents
放射線傷害を処置および予防する方法 Download PDFInfo
- Publication number
- JP2016534057A JP2016534057A JP2016525052A JP2016525052A JP2016534057A JP 2016534057 A JP2016534057 A JP 2016534057A JP 2016525052 A JP2016525052 A JP 2016525052A JP 2016525052 A JP2016525052 A JP 2016525052A JP 2016534057 A JP2016534057 A JP 2016534057A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- total body
- body irradiation
- radiation
- low anticoagulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
定義
「放射線傷害(damage)」という句は、本明細書において使用される場合、大量の電離放射線への曝露後に呈される健康への影響をいう。放射線傷害(damage)の例は細胞傷害(injury)、組織傷害(damage)、臓器機能不全、急性放射線症候群ならびに放射線が誘導する寿命短縮、白内障の発症および発がんなどの晩発性放射線影響を含むが、これらに限定されない。放射線傷害(damage)はさらに全身照射に関連する、または全身照射によって引き起こされる任意の他の傷害(damage)も含む。
全身照射への曝露
低抗凝固性ヘパリノイド
薬学的組成物
投与の様式
投与の予定
放射線傷害(damage)の処置および予防
この実験は、PBSまたは治療を伴わないコントロール群と比べて、全身照射後のODSHの間隔の投与はマウスの生存を改善することを実証する。(図1参照)
CD2F1オスマウス(Batch#7586 DOB12/23/2012)の体重を量り、平均体重の±20%の外側の動物を排除した。平均体重の±20%以内のマウスを、1箱あたり8動物の群に無作為化した。1処置グループあたり24動物がいた。AFRRI Cobalt 60 ガンマ放射線設備において、動物に0.6Gy/分の線量率の放射線を受けさせた。Lucite箱(1箱あたり8動物)において動物に照射し、プラスチックラックを使用して整列させて配置した(線量測定 02/25/2010)。動物を60分以下拘束し、放射期間終了時にケージに戻した。
等価物
参考によって援用
Claims (26)
- 全身照射に曝露される被験者における放射線傷害(damage)を処置または予防する方法であって、全身照射に曝露される被験者へ治療上または予防上有効な量の低抗凝固性ヘパリノイドを投与する工程を含む方法。
- 全身照射に曝露される被験者の寿命を延長する方法であって、全身照射に曝露される被験者へ治療上または予防上有効な量の低抗凝固性ヘパリノイドを投与する工程を含む方法。
- 前記低抗凝固性ヘパリノイドが約8kDa〜約15kDaの平均分子量を有する請求項1〜2のいずれかに記載の方法。
- 前記低抗凝固性ヘパリノイドが2−O位または3−O位を脱硫酸化または実質的に脱硫酸化される請求項1〜3のいずれかに記載の方法。
- 前記低抗凝固性ヘパリノイドが2−O位および3−O位を脱硫酸化または実質的に脱硫酸化される請求項1〜3のいずれかに記載の方法。
- 前記低抗凝固性ヘパリノイドが非経口的に投与される請求項1〜5のいずれかに記載の方法。
- 前記低抗凝固性ヘパリノイドが静脈または皮下投与される請求項6の方法。
- 全身照射への曝露後に、前記被験者に前記低抗凝固性ヘパリノイドが投与される請求項1〜7のいずれかに記載の方法。
- 全身照射への曝露後約60時間以内に、前記被験者に前記低抗凝固性ヘパリノイドが投与される請求項8の方法。
- 全身照射への曝露約2時間以上後に、前記被験者に前記低抗凝固性ヘパリノイドが投与される請求項8または9の方法。
- 全身照射への曝露前に、前記被験者に前記低抗凝固性ヘパリノイドが投与される請求項1〜10のいずれかに記載の方法。
- 前記被験者が0.1Gy/分以上の線量率で全身照射に曝露される請求項1〜11のいずれかに記載の方法。
- 前記被験者が0.5Gy/分以上の線量率で全身照射に曝露される請求項12の方法。
- 前記被験者が約2Gy以上の全身吸収線量を有する請求項1〜13のいずれかに記載の方法。
- 前記被験者が約6Gy以上の全身吸収線量を有する請求項14の方法。
- 前記被験者が約8Gy以上の全身吸収線量を有する請求項15の方法。
- 前記被験者への照射が約2時間以内の期間起こる請求項12〜16のいずれかに記載の方法。
- 前記被験者への照射が約1時間以内の期間起こる請求項17の方法。
- 前記低抗凝固性ヘパリノイドが1以上の用量において投与される請求項1〜18のいずれかに記載の方法。
- 前記1以上の用量が約1mg/kg〜約40mg/kgから独立して選択される請求項19の方法。
- 前記1以上の用量が約10mg/kg〜約30mg/kgから独立して選択される請求項20の方法。
- 全身照射に曝露される前記被験者が急性放射線症候群を有する請求項1〜21のいずれかに記載の方法。
- 全身照射に曝露される前記被験者が造血性症候群、胃腸性症候群および/もしくは脳血管性症候群の症状を現す請求項1〜22のいずれかに記載の方法。
- 症状が貧血症、感染症、出血、悪心、嘔吐、下痢、重度の脱水症状、敗血症および点状出血の1以上を含む請求項23の方法。
- 1以上の追加の処置を施す工程をさらに含む請求項1〜24のいずれかに記載の1つの方法。
- 前記1以上の追加の処置が輸血、抗生物質および骨髄移植から選択される請求項25の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361894343P | 2013-10-22 | 2013-10-22 | |
US61/894,343 | 2013-10-22 | ||
PCT/US2014/061634 WO2015061358A1 (en) | 2013-10-22 | 2014-10-21 | Methods of treating and preventing radiation damage |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016534057A true JP2016534057A (ja) | 2016-11-04 |
JP2016534057A5 JP2016534057A5 (ja) | 2017-11-30 |
Family
ID=52993467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016525052A Pending JP2016534057A (ja) | 2013-10-22 | 2014-10-21 | 放射線傷害を処置および予防する方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160287626A1 (ja) |
EP (1) | EP3060243A4 (ja) |
JP (1) | JP2016534057A (ja) |
KR (1) | KR20160101898A (ja) |
CN (1) | CN105848672A (ja) |
AU (1) | AU2014340238A1 (ja) |
CA (1) | CA2928585A1 (ja) |
HK (1) | HK1223021A1 (ja) |
IL (1) | IL245344A0 (ja) |
SG (1) | SG11201603081WA (ja) |
WO (1) | WO2015061358A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3122808A1 (en) | 2012-05-09 | 2013-11-14 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
KR20190063536A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 엔지켐생명과학 | 1-팔미토일-2-리놀레오일-3-아세틸글리세롤을 포함하는 급성 방사선 증후군의 예방 또는 치료용 조성물 |
CA3102284A1 (en) * | 2018-06-03 | 2019-12-12 | Glycomira Therapeutics, Inc. | Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy |
KR102090489B1 (ko) | 2018-10-19 | 2020-03-18 | 한국과학기술연구원 | 산화구리 나노입자로 도핑된 그래핀을 이용한 암모니아 가스 검출 센서 및 이를 포함하는 암모니아 가스 검출 장치 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0986401A1 (en) * | 1997-05-30 | 2000-03-22 | Arch Development Corporation | P-selectin translocation to vascular epithelial lumen by ionizing radiation |
JP2010534672A (ja) * | 2007-07-23 | 2010-11-11 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 終末糖化産物受容体(rage)の連結を阻止するための方法 |
JP2012529506A (ja) * | 2009-06-10 | 2012-11-22 | エーエクスセラ アクチエボラグ | 粘膜炎治療用組成物の使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1270034A (zh) * | 1999-11-04 | 2000-10-18 | 第一军医大学珠江医院 | 辅酶在组织细胞化学和辐射损伤防治中的应用 |
AU2006272780A1 (en) * | 2005-07-22 | 2007-02-01 | The Regents Of The University Of California | Heparin compostions and selectin inhibition |
MX2010010904A (es) * | 2008-04-04 | 2010-11-04 | Univ Utah Res Found | Eteres de glicosaminoglicosano semisinteticos alquilados, y metodos para elaborarlos y usarlos. |
US20120196828A1 (en) * | 2011-02-01 | 2012-08-02 | Paringenix, Inc. | Sensitization of cancer cells to treatment |
CA3122808A1 (en) * | 2012-05-09 | 2013-11-14 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
-
2014
- 2014-10-21 CN CN201480058093.1A patent/CN105848672A/zh active Pending
- 2014-10-21 KR KR1020167012984A patent/KR20160101898A/ko not_active Application Discontinuation
- 2014-10-21 JP JP2016525052A patent/JP2016534057A/ja active Pending
- 2014-10-21 US US15/031,248 patent/US20160287626A1/en not_active Abandoned
- 2014-10-21 CA CA2928585A patent/CA2928585A1/en not_active Abandoned
- 2014-10-21 WO PCT/US2014/061634 patent/WO2015061358A1/en active Application Filing
- 2014-10-21 EP EP14855522.0A patent/EP3060243A4/en not_active Withdrawn
- 2014-10-21 SG SG11201603081WA patent/SG11201603081WA/en unknown
- 2014-10-21 AU AU2014340238A patent/AU2014340238A1/en not_active Abandoned
-
2016
- 2016-05-01 IL IL245344A patent/IL245344A0/en unknown
- 2016-09-23 HK HK16111243.4A patent/HK1223021A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0986401A1 (en) * | 1997-05-30 | 2000-03-22 | Arch Development Corporation | P-selectin translocation to vascular epithelial lumen by ionizing radiation |
JP2010534672A (ja) * | 2007-07-23 | 2010-11-11 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 終末糖化産物受容体(rage)の連結を阻止するための方法 |
JP2012529506A (ja) * | 2009-06-10 | 2012-11-22 | エーエクスセラ アクチエボラグ | 粘膜炎治療用組成物の使用 |
Non-Patent Citations (2)
Title |
---|
AM. J. PHYSIOL. CELL PHYSIOL., vol. 299, JPN6018023781, 2010, pages 97 - 110, ISSN: 0003968714 * |
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, vol. 16, JPN6018023779, 2011, pages 138 - 146, ISSN: 0003968715 * |
Also Published As
Publication number | Publication date |
---|---|
EP3060243A4 (en) | 2017-03-29 |
WO2015061358A1 (en) | 2015-04-30 |
CN105848672A (zh) | 2016-08-10 |
HK1223021A1 (zh) | 2017-07-21 |
IL245344A0 (en) | 2016-06-30 |
AU2014340238A1 (en) | 2016-05-05 |
CA2928585A1 (en) | 2015-04-30 |
US20160287626A1 (en) | 2016-10-06 |
SG11201603081WA (en) | 2016-05-30 |
KR20160101898A (ko) | 2016-08-26 |
EP3060243A1 (en) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016534057A (ja) | 放射線傷害を処置および予防する方法 | |
Slavin et al. | Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. | |
Petkau et al. | Radioprotection of bone marrow stem cells by superoxide dismutase | |
Benacerraf | Influence of irradiation on resistance to infection | |
Broerse et al. | Mortality of monkeys after exposure to fission neutrons and the effect of autologous bone marrow transplantation | |
AU2012235881B2 (en) | Pharmaceutical preparation | |
KR20180038575A (ko) | 동위원소 제조 방법 | |
Furuta et al. | Rapid rise in FDG uptake in an irradiated human tumour xenograft | |
Howell et al. | Relative biological effectiveness of alpha-particle emitters in vivo at low doses | |
Yeung et al. | Effects of single doses of radiation on cardiac function in the rat | |
Bruland et al. | Radium-223: from radiochemical development to clinical applications in targeted cancer therapy | |
US20220401375A1 (en) | Protecting tissue and mitigating injury from radiation-induced ionizing events | |
Prasanna et al. | Modification of WR-2721 radiation protection from gastrointestinal injury and death in mice by 2-mercaptopropionylglycine | |
Du Toit et al. | The effect of ionizing radiation on the primate pancreas: an endocrine and morphologic study | |
CN108498788A (zh) | 经修饰的胸腺素β4的用途 | |
Jaroslow | The effects of X or neutron irradiation, India ink blockade, or splenectomy on innate immunity against Trypanosoma duttoni in mice | |
Carollo et al. | Lutetium-177 labeled peptides: the European Institute of Oncology Experience | |
Parke et al. | Ionizing radiation and life | |
Maurer | Basic Radiation Concepts and Biological Effects | |
Takahashi et al. | The distribution and retention of 89sr in mice after a single intravenous injection of high and low doses | |
Johnson et al. | Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy. | |
Walter | Malignant effusions treated by colloidal radioactive yttrium silicate | |
Brown | Clinical observations on cattle exposed to lethal doses of ionizing radiation | |
Khodamoradi et al. | Exploring the Potential of Metformin in Mitigating Radiation-induced Gastrointestinal and Hematopoietic System Injury in Rats After Whole-body X-ray Radiation: An Experimental Study | |
Tsuchiya et al. | The effects of tritiated water on the bone marrow cells in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171017 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171017 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180614 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180626 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190201 |